This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

49/100

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Tau biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background Cerebrovascular disease (CVD) and amyloid-β (Aβ) often coexist, but their influence on neurodegeneration and cognition in predementia stages remains unclear. We investigated the association between CVD and Aβ on neurodegenerative markers and cognition in patients without dementia. Methods We included 271 memory clinic patients with subjective or objective cognitive deficits but without dementia from the BioBank Alzheimer Center Limburg cohort (n = 99) and the LeARN (n = 50) and DESCRIPA (n = 122) multicenter studies.

What this study adds

Evidence grade: Moderate

The record lists 99 participants. In 271 memory clinic patients without dementia, this study looked at how cerebrovascular disease and amyloid-β relate to neurodegenerative markers and cognitive decline. It is an observational study of disease markers and progression, not a test of any treatment, cure, or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Bos, I., Verhey, F. R., Ramakers, I. H. G. B., Jacobs, H. I. L., Soininen, H., Freund-Levi, Y., et al. (2017). Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-017-0328-9

Vancouver

Bos I, Verhey FR, Ramakers IHGB, Jacobs HIL, Soininen H, Freund-Levi Y, et al. Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. Alzheimer's research & therapy. 2017. doi:10.1186/s13195-017-0328-9. PMID: 29284531.

BibTeX

@article{bos2017-29284531,
  author  = {Bos, I. and Verhey, F. R. and Ramakers, I. H. G. B. and Jacobs, H. I. L. and Soininen, H. and Freund-Levi, Y. and Hampel, H. and Tsolaki, M. and others},
  title   = {{Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline}},
  journal = {Alzheimer's research \& therapy},
  year    = {2017},
  doi     = {10.1186/s13195-017-0328-9},
  pmid    = {29284531},
  url     = {https://doi.org/10.1186/s13195-017-0328-9}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

How to read this study

Design: our record does not state a study design, so check the methods section of the original before weighing the result.
Size: the record lists 99 participants. Ask whether that is enough for the question, and who they were.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded moderate. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Moderate means the abstract mentions a cohort, case-control or longitudinal design. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

We investigated the association between CVD and Aβ on neurodegenerative markers and cognition in patients without dementia.
Methods We included 271 memory clinic patients with subjective or objective cognitive deficits but without dementia from the BioBank Alzheimer Center Limburg cohort (n = 99) and the LeARN (n = 50) and DESCRIPA (n = 122) multicenter studies.
CSF Aβ 1-42 and white matter hyperintensities (WMH) on magnetic resonance imaging (MRI) scans were used as measures of Aβ and CVD, respectively.
Individuals were classified into four groups based on the presence (+) or absence (-) of Aβ and WMH.

Why it matters

In 271 memory clinic patients without dementia, this study looked at how cerebrovascular disease and amyloid-β relate to neurodegenerative markers and cognitive decline. It is an observational study of disease markers and progression, not a test of any treatment, cure, or prevention.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Participants99
Evidence strengthModerate

How this study scored 49/100

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Alzheimer's research & therapy)
Journal's citation record	1 / 4	Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	2 / 5	2017 — within 10 year(s) of the newest study here
Sample size	1 / 4	99 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	4 / 7	Cited 63 times (OpenAlex, 2026-10-10)
Citations per year	2 / 5	5.7 citations a year over 11 year(s) since 2017
Impact for its field and year	3 / 6	Cited 5.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	2 / 6	Cited by 3 other studies in this library
Still being cited	1 / 4	Cited 14 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Stephanie J. B. Vos: h-index 41 (OpenAlex, whole career)
Institution's track record	1 / 3	Université Pierre-et-Marie-Curie: institution h-index 1,160 (OpenAlex)
Multicenter collaboration	3 / 3	OpenAlex lists 17 institution(s) in 5 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 29284531)
Free to read	2 / 2	Free to read
Total	49 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.

Later studies that cite this one

3 studies in the alzhub library list this one in their references.

Related studies in Tau biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →